Evidence map›Paper›PMID 39350426›Full record

ReviewRecent patents on biotechnology2025

A Patent Landscape on Methane Oxidizing Bacteria (MOB) or Methanotrophs.

Abhishek Bokad, Manasi Telang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent patents on biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Abhishek BokadCSIR-URDIP (Council of Scientific & Industrial Research - Unit for Research & Development of Information Products), S.No. 113 & 114, NCL Estate, Pashan Road, Pune 411008, Maharashtra, India.
Manasi TelangCSIR-URDIP (Council of Scientific & Industrial Research - Unit for Research & Development of Information Products), S.No. 113 & 114, NCL Estate, Pashan Road, Pune 411008, Maharashtra, India.ORCID 0000-0002-4956-5200

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methane-oxidizing bacteria (MOB) or methanotrophs are a category of bacteria that rely on methane as their primary carbon and energy source. Methane is the second most abundant greenhouse gas after carbon dioxide and is comparatively far more potent in trapping heat in the atmosphere. MOBs are important microorganisms in the global carbon cycle where they play a crucial role in the oxidation of methane. The present review provides a comprehensive patent landscape on technology development using MOB. The first patent in this technology domain was recorded in 1971, with a notable surge in activity observed in 2020. A detailed patent analysis revealed that the early inventions were mainly focused on the production of various metabolites and bioremediation using MOB. In the later years, patents were filed in the area of identification of various species of MOB and their large-scale production. From 2010 onwards, consistent patent filing was observed in the genetic engineering of MOB to enhance their methane oxidizing capacity. The United States and China have emerged as the global leaders in terms of patent filing in this technology space. Precigen Inc. and Exxon Research Engineering Co., US were the top patent assignees followed by the University of Tsinghua and Calysta Inc. The Highest number of patent applications have claimed metabolite production by using MOB followed by their use in bioremediation. Methylosinus has emerged as the predominant microorganism of choice for methane oxidation applications.

Indexed as

MethaneMethylococcaceaePatents as TopicBiodegradation, EnvironmentalOxidation-ReductionMethanebioremediationMethanemethane oxidizing bacteriamethanotrophsoxidation applications.patent landscape

Identifiers

PMID39350426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.